Factors Influencing the Background Parenchymal Enhancement in Follow-Up Breast MRI after Adjuvant Endocrine Therapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate factors influencing the evaluation of backgroundparenchymal enhancement (BPE) at follow-up breast magnetic resonance imaging(MRI) after adjuvant endocrine therapy. Materials and Methods: One hundred twelve women with breast cancer and MRIof the contralateral unaffected breast before and after endocrine therapy wereidentified. Two readers in consensus performed blinded side-by-side comparison ofBPE (minimal, mild, moderate, and marked) before and after therapy with categoricalscales. Age, body mass index, menopausal status, treatment regimen (selectiveestrogen receptor modulator or aromatase inhibitor), chemotherapy, follow-upduration, BPE at baseline MRI, MRI field strength before and after therapy, andrecurrence were analyzed for their influences on decreased BPE. Results: Younger age, premenopausal status, treatment with selective estrogenreceptor modulator, MRI field strength, and moderate or marked baseline BPE weresignificantly associated with decreased BPE. In multivariate analysis, MRI fieldstrength and baseline BPE showed a significant association. Conclusion: MRI field strength and baseline BPE before and after therapy .wereassociated with decreased BPE at post-therapy, follow-up MRI.
Abstract
Purpose: To investigate factors influencing the evaluation of backgroundparenchymal enhancement (BPE) at follow-up breast magnetic resonance imaging(MRI) after adjuvant endocrine therapy. Materials and Methods: One hundred twelve women with breast cancer and MRIof the contralateral unaffected breast before and after endocrine therapy wereidentified. Two readers in consensus performed blinded side-by-side comparison ofBPE (minimal, mild, moderate, and marked) before and after therapy with categoricalscales. Age, body mass index, menopausal status, treatment regimen (selectiveestrogen receptor modulator or aromatase inhibitor), chemotherapy, follow-upduration, BPE at baseline MRI, MRI field strength before and after therapy, andrecurrence were analyzed for their influences on decreased BPE. Results: Younger age, premenopausal status, treatment with selective estrogenreceptor modulator, MRI field strength, and moderate or marked baseline BPE weresignificantly associated with decreased BPE. In multivariate analysis, MRI fieldstrength and baseline BPE showed a significant association. Conclusion: MRI field strength and baseline BPE before and after therapy .wereassociated with decreased BPE at post-therapy, follow-up MRI.
참고문헌 (27)
- Musgrove EA, "Biological determinants of endocrine resistance in breast cancer", Nat Rev Cancer, 9, pp.631~643 (2009)
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), "Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials", Lancet, 378, pp.771~784 (2011)
- Cuzick J, "Breast density predicts endocrine treatment outcome in the adjuvant setting", Breast Cancer Res, 14, pp.109~ (2012)
- Kim J, "Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer", Breast Cancer Res, 14, pp.R102~ (2012)
- Brennan S, "Breast MRI screening of women with a personal history of breast cancer", AJR Am J Roentgenol, 195, pp.510~516 (2010)
- Mousa NA, "The effect of acute aromatase inhibition on breast parenchymal enhancement in magnetic resonance imaging: a prospective pilot clinical trial", Menopause, 19, pp.420~425 (2012)
- King V, "Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging", Radiology, 264, pp.670~678 (2012)
- Kuhl CK, "Healthy premenopausal breast parenchyma in dynamic contrastenhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency", Radiology, 203, pp.137~144 (1997)
- Muller-Schimpfle M, "Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast", Radiology, 203, pp.145~149 (1997)
- Chen JH, "Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI", Magn Reson Imaging, 31, pp.1465~1471 (2013)
- Pfleiderer SO, "Changes in magnetic resonance mammography due to hormone replacement therapy", Breast Cancer Res, 6, pp.R232~R238 (2004)
- Delille JP, "Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging--initial observations", Radiology, 235, pp.36~41 (2005)
- Eng-Wong J, "Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer", Cancer Epidemiol Biomarkers Prev, 17, pp.1696~1701 (2008)
- Oksa S, "Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia", Acta Radiol, 50, pp.984~989 (2009)
- King V, "Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging", Breast J, 18, pp.527~534 (2012)
- Schrading S, "Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study", Radiology, 271, pp.45~55 (2014)
- Morris E, "ACR BI-RADS atlas, breast imaging reporting and data system" (2013), American College of Radiology
- Morris EA, "Diagnostic breast MR imaging: current status and future directions", Radiol Clin North Am, 45, pp.863~880 (2007)
- Uematsu T, "Background enhancement of mammary glandular tissue on breast dynamic MRI: imaging features and effect on assessment of breast cancer extent", Breast Cancer, 19, pp.259~265 (2012)
- Cubuk R, "Correlation between breast density in mammography and background enhancement in MR mammography", Radiol Med, 115, pp.434~441 (2010)
- Harris JR, "Disease of the breast" (2010), Lippincott Williams & Wilkins
- Raza S, "Implementing a breast MR imaging program: all things considered", Magn Reson Imaging Clin N Am, 18, pp.187~198 (2010)
- Rahbar H, "Clinical and technical considerations for high quality breast MRI at 3 Tesla", J Magn Reson Imaging, 37, pp.778~790 (2013)
- Chatterji M, "Optimizing 1.5-Tesla and 3-Tesla dynamic contrast-enhanced magnetic resonance imaging of the breasts", Magn Reson Imaging Clin N Am, 18, pp.207~224 (2010)
- Kuhl CK, "Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience", Radiology, 239, pp.666~676 (2006)
- Pinker K, "A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results", Invest Radiol, 44, pp.553~558 (2009)
- Rakow-Penner R, "Relaxation times of breast tissue at 1.5T and 3T measured using IDEAL", J Magn Reson Imaging, 23, pp.87~91 (2006)